These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 36063602)
1. Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients. Huang Y; Xu C; Sun Y; Wang W; Li X; Liao J; Pang L; Zeng L; Li J; Wang X; Zhang Q; Xie Z; Xiao L; Gan J; Fang W Lung Cancer; 2022 Oct; 172():117-123. PubMed ID: 36063602 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X. Hao Y; Xu M; Zhou H; Si J; Fang Y; Xu C; Song Z Med Oncol; 2022 Dec; 40(1):34. PubMed ID: 36460861 [TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878 [TBL] [Abstract][Full Text] [Related]
4. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC. Pang L; Huang Y; Zhuang W; Zhang Y; Liao J; Hao Y; Hao F; Wang G; Chen ZC; Zhu Y; Li M; Song Z; Deng BP; Li J; Zhang L; Fang W Clin Cancer Res; 2024 Jun; 30(12):2636-2646. PubMed ID: 38578683 [TBL] [Abstract][Full Text] [Related]
5. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report. Van Acker L; Stevens D; Vermaelen K; Surmont V J Med Case Rep; 2021 Nov; 15(1):562. PubMed ID: 34809713 [TBL] [Abstract][Full Text] [Related]
6. A Lung Adenocarcinoma Patient With a Rare Wei Y; Cui Y; Guo Y; Li L; Zeng L Front Oncol; 2021; 11():700345. PubMed ID: 34178699 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population. Sutandyo N; Hanafi A; Jayusman M Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459 [TBL] [Abstract][Full Text] [Related]
10. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study. Kim TH; Choi JH; Ahn MS; Lee HW; Kang SY; Choi YW; Koh YW; Sheen SS BMC Cancer; 2024 Jan; 24(1):70. PubMed ID: 38216948 [TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis. Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899 [TBL] [Abstract][Full Text] [Related]
12. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
13. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis. Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465 [TBL] [Abstract][Full Text] [Related]
14. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047 [TBL] [Abstract][Full Text] [Related]